Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CORVUS PHARMACEUTICALS, INC.

(CRVS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences

09/07/2021 | 04:06pm EDT

BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company’s management will participate in two upcoming investor conferences in September:

  • The first conference is the H.C. Wainwright Annual Global Investment Conference, which is taking place September 13-15, 2021. The Company will conduct one-on-one meetings with investors at this conference and a pre-recorded corporate overview presentation by Richard A. Miller, M.D., president and chief executive officer of Corvus, will be available to play on-demand starting at 7:00 am ET on September 13. Attendees can register to view the webcast here.

  • The second conference is the Cantor Virtual Global Healthcare Conference, which is taking place September 27-30, 2021. The Company will conduct one-on-one meetings with investors at this conference and a virtual corporate overview presentation will be conducted by Dr. Miller at 3:20-3:50 pm ET on September 29. Attendees can register for the virtual presentation here.

Attendees can also access the webcast of the presentations noted above via the investor relations section of the Corvus website and replays will be available for 90 days following the events.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidate is mupadolimab (CPI-006), a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and is currently being evaluated in Phase 1b/2 clinical trials in patients with either head and neck cancers or lung cancers. The Company’s second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies, and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com 

MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com 


Primary Logo


ę GlobeNewswire 2021
All news about CORVUS PHARMACEUTICALS, INC.
04:06pCorvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval fo..
AQ
09/22Health Care Stocks Follow Market Higher Wednesday
MT
09/22Health Care Stocks Edge Higher Premarket Wednesday
MT
09/22CORVUS PHARMACEUTICALS : Reports Results of Phase 3 Trial of Mupadolimab; Shares Fall Pre-..
MT
09/22Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology..
GL
09/22Corvus Pharmaceuticals Provides Updates on Mupadolimab
CI
09/17Top Premarket Gainers
MT
09/07Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
GL
08/17CORVUS PHARMACEUTICALS : Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-1 i..
AQ
08/17CORVUS PHARMACEUTICALS' : Chinese Partner Gets Regulatory Nod to Conduct Early Stage Study..
MT
More news
Analyst Recommendations on CORVUS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -40,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,75x
Yield 2021 -
Capitalization 193 M 193 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 5,67x
Nbr of Employees 42
Free-Float 88,4%
Chart CORVUS PHARMACEUTICALS, INC.
Duration : Period :
Corvus Pharmaceuticals, Inc. Technical Analysis Chart | CRVS | US2210151005 | MarketScreener
Technical analysis trends CORVUS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 4,56 $
Average target price 5,13 $
Spread / Average Target 12,4%
EPS Revisions
Managers and Directors
Richard A. Miller Chairman, President & Chief Executive Officer
Leiv Lea Chief Financial Officer
Suresh Mahabhashyam Vice President-Clinical Development
Peter A. Thompson Independent Director
Elisha P. Gould Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CORVUS PHARMACEUTICALS, INC.28.09%189
MODERNA, INC.226.29%139 557
LONZA GROUP AG32.63%60 898
IQVIA HOLDINGS INC.41.93%48 923
SEAGEN INC.-0.30%32 330
CELLTRION, INC.-39.00%26 036